Immunohistochemistry of Five Molecular Markers for Typing and Management of Ameloblastomas: A Retrospective Analysis of 40 Cases
- 105 Downloads
The aims of this study are to elucidate if molecular markers can be used to differentiate between the two main types of ameloblastoma (unicystic and solid/multicystic), and to determine whether a biologically ‘less-aggressive’ subtype exists.
A retrospective analysis of 33 solid/multicystic ameloblastomas and six unicystic ameloblastomas was completed using immunohistochemistry for five molecular markers: P16, P53, MMP-9, Survivin, and Ki-67. Tumors were graded as either negative or positive (mild, moderate, strong), and the results were related to both ameloblastoma subtypes and outcomes following treatment.
Unicystic ameloblastomas were more likely to test strongly positive for P53 than solid/multicystic ameloblastomas (p < 0.05), whereas the latter were more likely to be negative for Survivin (p < 0.05). Solid/multicystic and Type 3 unicystic ameloblastomas that were positive for P16, but also negative for MMP-9 and Survivin, were less likely to recur than all other tumors (p < 0.05). The proliferation index of an ameloblastic carcinoma (11 %) was shown to be higher than benign ameloblastomas (4.5 %).
Immunohistochemistry can be valuable in lesions where histological sub-typing of an ameloblastoma is unclear. A biologically ‘less-aggressive’ subtype may exist, and hence further research into this area is required.
KeywordsP16 Markers Diagnosis Outcome Ameloblastoma
The authors would like to acknowledge the staff at the Anatomical and Pathology Laboratory at The Royal Melbourne Hospital. Special thanks to Associate Professor Nastri and Associate Professor Wiesenfeld for their assistance in this study. A research grant was kindly provided by the Australia and New Zealand Association of Oral and Maxillofacial Surgeons (ANZAOMS) Research and Education Foundation Inc. and Trust.
- 4.Gardner D, Heikinheimo K, Shear M, Philipsen H, Coleman H (2005) Ameloblastoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. International Agency for Research on Cancer, LyonGoogle Scholar
- 5.Artese L, Lessi G, Piattelli A, Rubini C, Goteri G, Pernotti V, Piccirilli M, Carinci F (2008) p16 expression in odontogenic cysts. Dent Res J 5(2):61–64Google Scholar
- 11.Sharifi-Sistani N, Zartab H, Babakoohi S, Saghravanian N, Jamshidi S, Esmaili H, Mohtasham N, Zamanzadeh M, Abbaszadeh-Bidokhty H (2011) Immunohistochemical comparison of the expression of p53 and MDM2 proteins in ameloblastomas and keratocystic odontogenic tumors. J Craniofac Surg 22(5):1652–1656. doi: 10.1097/SCS.0b013e31823188e9 CrossRefPubMedGoogle Scholar
- 17.Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, El-Mofty SK (2010) p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 34(8):1088–1096. doi: 10.1097/PAS.0b013e3181e84652 CrossRefPubMedGoogle Scholar
- 18.Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG (2003) Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 163(2):477–491CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Henriques AC, Vasconcelos MG, Galvao HC, de Souza LB, de Almeida Freitas R (2011) Comparative analysis of the immunohistochemical expression of collagen IV, MMP-9, and TIMP-2 in odontogenic cysts and tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(4):468–475. doi: 10.1016/j.tripleo.2011.05.033 CrossRefPubMedGoogle Scholar
- 30.Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, de Almeida OP, Carrasco-Daza D, Farfan-Morales JE, Molina-Frechero N, Damian-Matsumura P (2009) Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma. Pathol Int 59(4):229–233. doi: 10.1111/j.1440-1827.2009.02355.x CrossRefPubMedGoogle Scholar